Recent Updates
Recently added Catalysts

Dermacyn

Phase 2

Foot Ulcer, Diabetic | Small molecule | Other |Sonoma Pharmaceuticals, Inc.|Last Updated: Jan 14, 2008

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment65
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00516958Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot InfectionsPHASE2 COMPLETED 65May 1, 2007Dec 1, 2007Jan 14, 200816 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To compare the rates of clinical success (cure + improvement) of Topical Dermacyn™ vs. Oral Levofloxacin vs. Combined therapy, in patients with mild diabetic foot infections in non ischemic ulcers
Visit 3 (Day 10); Visit 4 (Day 24)
Secondary Endpoints
To compare the treatment groups with respect to microbiological outcome. Incidence of adverse events and other safety outcomes
Visit 2 (Day 3); Visit 3 (Day 10)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALTopical Dermacyn
2ACTIVE_COMPARATORTopical Dermacyn and levofloxacin
3ACTIVE_COMPARATORTopical saline and levofloxacin
Interventions
NameTypeDescription
Topical DermacynDRUGTopical Dermacyn once a day for 10 Days
Topical Dermacyn and LevofloxacinDRUGTopical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
Topical Saline and LevofloxacinDRUGTopical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: * A patient must meet all of the following inclusion criteria to be enrolled in the study: 1. Males and females \> 18 years of age with diabetes mellitus (type 1 or type 2, controlled). 2. Presence of infected, non-ischemic diabetic foot ulcer that involves skin and deeper ...

Countries:United States
Unlock Eligibility Criteria